These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17404598)

  • 81. Looking back at multidrug resistance (MDR) research and ten mistakes to be avoided when writing about ABC transporters in MDR.
    Borst P
    FEBS Lett; 2020 Dec; 594(23):4001-4011. PubMed ID: 33111311
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors?
    Hegedus C; Ozvegy-Laczka C; Szakács G; Sarkadi B
    Curr Cancer Drug Targets; 2009 May; 9(3):252-72. PubMed ID: 19442047
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells.
    Porro A; Haber M; Diolaiti D; Iraci N; Henderson M; Gherardi S; Valli E; Munoz MA; Xue C; Flemming C; Schwab M; Wong JH; Marshall GM; Della Valle G; Norris MD; Perini G
    J Biol Chem; 2010 Jun; 285(25):19532-43. PubMed ID: 20233711
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Regulation of ABC transporter function via phosphorylation by protein kinases.
    Stolarczyk EI; Reiling CJ; Paumi CM
    Curr Pharm Biotechnol; 2011 Apr; 12(4):621-35. PubMed ID: 21118091
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Transport proteins of the ABC family and multidrug resistance of tumor cells.
    Stavrovskaya AA; Stromskaya TP
    Biochemistry (Mosc); 2008 May; 73(5):592-604. PubMed ID: 18605983
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Correlation between multi-drug resistance-associated membrane transport in clonal cancer cells and the cell cycle phase.
    Koshkin V; Krylov SN
    PLoS One; 2012; 7(7):e41368. PubMed ID: 22848474
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The ABC of dendritic cell development and function.
    van de Ven R; Scheffer GL; Scheper RJ; de Gruijl TD
    Trends Immunol; 2009 Sep; 30(9):421-9. PubMed ID: 19699682
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy.
    Wu CP; Ohnuma S; Ambudkar SV
    Curr Pharm Biotechnol; 2011 Apr; 12(4):609-20. PubMed ID: 21118092
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Prediction of the response to chemotherapy in ovarian cancers.
    Surowiak P
    Folia Morphol (Warsz); 2006 Nov; 65(4):285-94. PubMed ID: 17171607
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Drug resistance in the mouse cancer clinic.
    Rottenberg S; Borst P
    Drug Resist Updat; 2012; 15(1-2):81-9. PubMed ID: 22335919
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Quercetin: a potential drug to reverse multidrug resistance.
    Chen C; Zhou J; Ji C
    Life Sci; 2010 Sep; 87(11-12):333-8. PubMed ID: 20637779
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Microarray Expression Profiling of ABC Transporters in Human Breast Cancer.
    Gillet JP; Schneider J; Bertholet V; DE Longueville F; Remacle J; Efferth T
    Cancer Genomics Proteomics; 2006; 3(2):97-106. PubMed ID: 31394687
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Investigating the effects of ABC transporter-based acquired drug resistance mechanisms at the cellular and tissue scale.
    Liu C; Krishnan J; Xu XY
    Integr Biol (Camb); 2013 Mar; 5(3):555-68. PubMed ID: 23364280
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs.
    Quintieri L; Fantin M; Vizler C
    Adv Exp Med Biol; 2007; 593():95-104. PubMed ID: 17265720
    [TBL] [Abstract][Full Text] [Related]  

  • 95. ABC transporters and cancer. Preface.
    Schuetz JD; Ishikawa T
    Adv Cancer Res; 2015; 125():xv-xvii. PubMed ID: 25640273
    [No Abstract]   [Full Text] [Related]  

  • 96. The use of proteomic technologies to study molecular mechanisms of multidrug resistance in cancer.
    Cao Y; Li Z; Mao L; Cao H; Kong J; Yu B; Yu C; Liao W
    Eur J Med Chem; 2019 Jan; 162():423-434. PubMed ID: 30453249
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Analysis of expression of drug resistance-linked ABC transporters in cancer cells by quantitative RT-PCR.
    Calcagno AM; Ambudkar SV
    Methods Mol Biol; 2010; 637():121-32. PubMed ID: 20419432
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Glycosphingolipids and drug resistance.
    Gouaze-Andersson V; Cabot MC
    Biochim Biophys Acta; 2006 Dec; 1758(12):2096-103. PubMed ID: 17010304
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Multidrug resistance in breast cancer: from in vitro models to clinical studies.
    Wind NS; Holen I
    Int J Breast Cancer; 2011; 2011():967419. PubMed ID: 22332018
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Genomics and cancer drug resistance.
    Rodrigues AS; Dinis J; Gromicho M; Martins C; Laires A; Rueff J
    Curr Pharm Biotechnol; 2012 Apr; 13(5):651-73. PubMed ID: 22122479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.